Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eidos Therapeutics, Inc. (EIDX)
|
Add to portfolio |
|
|
|
| Price: |
$72.05
| | Metrics |
| OS: |
38.7
|
M
| |
-82
|
% ROE
|
| Market cap: |
$2.79
|
B
| |
-1320
|
% ROIC
|
|
Net cash:
|
$131
|
M
| |
$3.38
|
per share
|
|
EV:
|
$2.66
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($99.6)
|
M
| |
|
|
|
EBIT
|
($99.9)
|
M
| |
|
|
| EPS |
($2.64)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 26.7 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 2.5 | 0.0 | 0.0 | 0.0 |
| Gross profit | 24.2 | 0.0 | 0.0 | 0.0 |
| Gross margin | 90.6% | | | |
| Research and development | 46.9 | 28.5 | 9.3 | 1.7 |
| General and administrative | 17.8 | 9.2 | 2.7 | 0.7 |
| EBIT | -40.5 | -37.8 | -12.0 | -2.4 |
| EBIT margin | -151.6% | | | |
| Pre-tax income | -37.8 | -40.7 | -11.9 | -2.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -37.8 | -39.8 | -11.9 | -2.5 |
| Net margin | -141.8% | | | |
| |
| Diluted EPS | ($1.02) | ($1.81) | ($2.76) | ($0.69) |
| Shares outstanding (diluted) | 37.1 | 22.0 | 4.3 | 3.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|